Revumenib

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [1].

Product Specifications

CAS Number

[2169919-21-3]

Product Name Alternative

SNDX-5613

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/revumenib.html

Purity

99.99

Solubility

DMSO : ≥ 25 mg/mL

Smiles

O=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(CC)=O)CC5)CC4)C3

Molecular Formula

C32H47FN6O4S

Molecular Weight

630.82

Precautions

H302, H315, H319

References & Citations

[1]A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory) .